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Abstract
Background Gastric cancer (GC) is the third most common cause of cancer death. Intestinal type GC is a molecularly diverse 
disease. Formins control cytoskeletal processes and have been implicated in the progression of many cancers. Their clinical 
significance in GC remains unclear. Here, we characterize the expression of formin proteins FHOD1 and FMNL1 in intes-
tinal GC tissue samples and investigate their association with clinical parameters, GC molecular subtypes and intratumoral 
T lymphocytes.
Methods The prognostic significance of FHOD1 and FMNL1 mRNA expression was studied with Kaplan–Meier analyses 
in an online database. The expression of FHOD1 and FMNL1 proteins was characterized in GC cells, and in non-neoplastic 
and malignant tissues utilizing tumor microarrays of intestinal GC representing different molecular subtypes. FHOD1 and 
FMNL1 expression was correlated with clinical parameters, molecular features and T lymphocyte infiltration. Immunohis-
tochemical expression of neither formin correlated with survival.
Results Kaplan–Meier analysis associated high FHOD1 and FMNL1 mRNA expression with reduced overall survival (OS). 
Characterization of FHOD1 and FMNL1 in GC cells showed cytoplasmic expression along the actin filaments. Similar pattern 
was recapitulated in GC tissue samples. Elevated FMNL1 was associated with larger tumor size and higher disease stage. 
Downregulation of FHOD1 associated with TP53-mutated GC tumors. Tumor cell FHOD1 expression strongly correlated 
with high numbers of tumor-infiltrating CD8 + lymphocytes.
Conclusions FHOD1 and FMNL1 proteins are expressed in the tumor cells of intestinal GC and significantly associate with 
clinical parameters without direct prognostic significance. FHOD1 correlates with high intratumoral CD8 + T lymphocyte 
infiltration in this cohort.
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Introduction
Gastric cancer (GC) is the fifth most common cancer type 
globally and the third most common cause of cancer death. 
Despite a few notable advances in the systemic management 
of GC, the overall prognosis of patients with metastatic dis-
ease remains poor [1]. Intestinal type GC is a heterogeneous 
and complex disease; it is the GC type with the most molec-
ular diversity [2]. The new molecular classification of gastric 
cancer provides a vital insight knowledge on the molecular 
and biological behavior of gastric cancer [3, 4]. GC has been 
recognized as a collection of various molecularly driven par-
ticular entities rather than a single disease. Among these 
molecular GC subtypes, the most immunogenic tumors are 
 * Naziha Mansuri 
 Naziha.i.mansuri@utu.fi
1 Institute of Biomedicine and FICAN West Cancer Centre, 
University of Turku and Turku University Hospital, 
Kiinamyllynkatu 10, 20520 Turku, Finland
2 Department of Pathology, Turku University Hospital 
and University of Turku, Kiinamyllynkatu 10, 20520 Turku, 
Finland
3 Medicum, Research Program in Systems Oncology 
and HUSLAB, University of Helsinki and Helsinki 
University Hospital, Haartmaninkatu 3, 00014 Helsinki, 
Finland
4 Department of Oncology, University of Turku and Turku 
University Hospital, Kiinamyllynkatu 4-8, 20521 Turku, 
Finland
 N. Mansuri et al.
1 3
the Microsatellite instable (MSI) and Epstein-Barr Virus 
positive (EBV +) GC subtypes. The MSI and EBV + GC has 
been studied extensively for the possibility of the utilization 
of targeted immunotherapy [5].
Formins are molecular scaffolds that nucleate actin by 
a pathway distinct from Arp2/3 complex, linking signal 
transduction to actin reorganization and gene transcription. 
Despite the significant discoveries on formins’ role in cell 
biology and embryogenesis, few studies have directly impli-
cated their role in disease pathogenesis and tumor progres-
sion in general, and in gastric cancer in particular. Formin 
homology two domain-containing protein one or FHOD1, 
is a crucial regulator of cellular actin dynamics [6]. Pre-
vious studies by us and others implicate FHOD1 as an 
essential participant in cancer cell migration, invasion, and 
stress fiber formation [7–10]. FHOD1 has been implicated 
as one of the crucial genes linked with advanced disease 
and metastasis in GC patients [11]. In addition, FHOD1 is 
frequently overexpressed in triple-negative breast cancers 
[7]. The mechanisms that regulate formin expression are 
poorly known but may involve signaling pathways derailed 
in cancers. Human leukocyte formin or FMNL1 is mainly 
expressed in lymphoid tissues, such as the spleen and thy-
mus, and the haematopoietic tissues; in addition, it is overex-
pressed in human hematological malignancies, more specifi-
cally in non-Hodgkin lymphoma and in leukemic cell lines 
[12–14]. FMNL1 is crucial for cellular processes in T lym-
phocytes and macrophages [15, 16]. The possible relation-
ship between FMNL1 and FHOD1 with the tumor immune 
infiltrating lymphocytes in GC is still largely unstudied.
Here, we analyzed the expression of FHOD1 and FMNL1 
in intestinal-type tumor samples of the stomach, gastroin-
testinal junction and distal esophagus and investigated their 
association with clinical data, including GC molecular sub-
types. In addition, we characterized FHOD1 and FMNL1 
expression in cultured gastric cancer cells. Our study is 
the first one to characterize these formins in intestinal gas-
tric cancer tissue samples and investigate the correlation 
between cancer cell-specific FHOD1 and FMNL1 protein 
expression and intratumoral T lymphocyte infiltration.
Materials and methods
Analysis of mRNA data from public databases
The prognostic significance of FHOD1 and FMNL1 mRNA 
expression in gastric tumors was assessed by utilizing pub-
licly available online database km-plotter (www. kmplot. 
com) [17]. Kaplan–Meier survival analyses were done for 
intestinal gastric cancer samples (n = 320), cut-off value was 
291 (range 82–1706) for FHOD1 (probe: 218530_at) and 
108 (range 2–1050) for FMNL1 (probe: 204789_at).
Gastric cancer cell lines
Gastric cancer cell lines AGS, MKN28, and MKN45 were 
cultured in DMEM (Lonza, Basel, Switzerland) containing 
10% fetal bovine serum (Biowest, Nuaillé, France), supple-
mented with 5 mM ultraglutamine and 100 U/ml penicil-
lin–streptomycin (Gibco, CA, USA). The AGS cell line was 
derived from the primary gastric cancer of a 54-year-old 
female which exhibited characteristics of both Lauren sub-
types [18]. The MKN28 cell line was derived from a lymph 
node metastasis of a 70-year-old female with a well-differ-
entiated primary gastric cancer of intestinal histology [19]. 
The MKN45 cell line was derived from the liver metastasis 
of a 62-year-old patient with a poorly differentiated primary 
gastric cancer of diffuse histology [19].
Western blotting
Western blot samples from gastric cancer cell lines were col-
lected and processed as described elsewhere [18]. The rab-
bit anti-human FHOD1 or FMNL1 (1:1000, Sigma-Aldrich, 
St. Louis, MO) antibody was incubated overnight at 4 °C. 
Rabbit polyclonal to GAPDH—HRP conjugated (Abcam, 
Cambridge, UK) was used 1:5000 as a control for protein 
loading. The secondary antibodies were HRP-conjugated 
swine anti-rabbit and HRP-conjugated rabbit anti-mouse 
immunoglobulins (1:3000, Dako, Glostrup, Denmark). 
Membranes were washed three times with TBST between 
the different steps.
Cell immunofluorescence staining and microscopy
Cells were plated on gelatin (Sigma-Aldrich) precoated cov-
erslips (13 mm) and grown in complete medium for 24 h. 
The cells were fixed and stained as described in Peippo et al. 
[20]. Primary rabbit anti-human FHOD1 or FMNL1 anti-
bodies (1:200, Sigma-Aldrich) were incubated for 1 h at RT. 
Secondary antibodies were Alexa Fluor 568 goat anti-rabbit 
IgG (1:500, Invitrogen, Carlsbad, CA). The filamentous actin 
was visualized with Alexa Fluor 488-conjugated phalloidin 
(1:500, Invitrogen). The mounting media contained DAPI 
for staining the nuclei  (ProLong® Gold Antifade Mountant 
with DAPI, Life Technologies). For negative controls, the 
cells were stained using secondary and phalloidin antibodies 
only. Images were taken with a Nikon Elipse Ni fluorescence 
microscope (Nikon Instruments).
Patients and tumor specimens
The collection and characteristics of the study cohort have 
been previously reported [21]. In brief, a total number 
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of 190 patients with intestinal-type gastric adenocarci-
nomas were selected out of a consecutive series of 244 
patients diagnosed with adenocarcinoma of the stomach, 
gastro-esophageal junction (GOJ) or distal esophagus at 
the Turku University Hospital between years 1993 and 
2012. For confirmation of diagnosis and adequacy of mate-
rial, all corresponding haematoxylin–eosin (H&E) stained 
slides were reviewed. Tumor stage was assessed accord-
ing to the current TNM classification manual [22]. The 
relevant clinical information was collected from the medi-
cal records. The median follow-up time was 125 months. 
Among these patients, 6.8% (13/190) received preopera-
tive chemotherapy. Helicobacteria pylori status was avail-
able for 78/190 patients of which 20/78 were positive for 
H. pylori.
The intestinal-type cancers were classified based on 
the following criteria: EBER in situ hybridization positive 
tumors were classified as EBV-positive, tumors showing a 
complete loss of nuclear reactivity of at least one of the 
mismatch repair protein (MMR) markers (MLH1, MSH2, 
MSH6, PMS2) were classified as mismatch repair-deficient 
(MMR-D) and tumors with complete loss of or strong dif-
fuse TP53 nuclear immunoreactivity were classified as 
TP53 aberrant. Tumors showing none of these alterations 
were classified as “other” [21]. 186 tumors were eligible for 
molecular classification. The reporting of the study has been 
performed following the current recommendations [23]. The 
study cohort characteristics are summarized in Table 1.
Immunohistochemistry (IHC) of FHOD1 and FMNL1 
formin expression
The expression of formins FHOD1 and FMNL1 in clinical 
gastric cancer samples was studied utilizing a ngTMA (next-
generation tissue microarray). TMA construction has been 
described previously [21]. Briefly, whole slide images of 
representative tumors were sectioned at 4 µm, H&E stained, 
scanned and uploaded into a web portal (casecenter.utu.fi) 
for annotation. Four individual cores (1.0 mm in diameter) 
were collected from each tumor, two from the central area 
and two from the invasive front. In addition, normal gastric 
mucosa was included. FHOD1 and FMNL1 staining was 
performed according to the streptavidin-peroxidase method 
using a Labvision staining device (Thermo Fisher Scientific, 
Fremont, CA). Rabbit anti-human polyclonal monospecific 
antibodies were used (FHOD1 (HPA024468), dilution 1:150, 
Sigma-Aldrich, St Louis, MA and FMNL1 (20466-1-AP), 
dilution 1:500), Proteintech, Chicago, IL. Sample cores with 
less than 25% of tumor tissue were excluded from scoring. 
FMNL1 and FHOD1 stainings were scored as 0 (negative), 
1 (weak), 2 (intermediate), or 3 (strong). Examples of the 
stainings are presented in Fig. 3b.
Statistical analyses
The intensity of FHOD1 and FMNL1 expression was ana-
lyzed for association with clinical variables and differences 
among the molecular subtypes using χ2 test or Fisher’s exact 
test. Kaplan–Meier log-rank test was used for univariate sur-
vival analyses. Only recurrences ≥ 6 months after the time 
of diagnosis were considered relevant for the recurrence-
free survival (RFS) which was calculated from the time of 
diagnosis to the time of first recurrence, death of any cause, 
or to the last follow-up date. Overall survival (OS) was cal-
culated from the time of diagnosis to the time of death of 
any cause or the last follow-up date. Correlation of FHOD1 
and FMNL1 expression to the number of lymphocytes in the 
same tissue samples were analyzed with one-way ANOVA 
Table 1  Patient characteristics of the intestinal-type esophagogastric 
adenocarcinomas
a MMR-D mismatch repair deficient, MMR-P mismatch repair profi-
cient, EBV Epstein–Barr virus
b The groups were not mutually exclusive. The percentages are cal-
culated as a proportion of the 186/190 tumors eligible for molecular 
characterization
Number of patients n (%)
All 190




Site of primary tumor





 Grade 1 17 (8.9)
 Grade 2 93 (48.9)







 Alive and free of disease 34 (17.9)
 Alive with disease 1 (0.5)
 Deceased 155 (81.6)
Molecular  subtypesa
 EBV + 17 (9.1)b
 MMR-D 19 (10.2)
 TP53 aberrant 103 (55.4)
 Others 52 (28.0)
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or independent samples T test (with Levene’s test). Statisti-
cal analyses were performed with IBM SPSS Statistics for 
Windows, version 27.0 (IBM Corporation, Armonk, NY). P 
values < 0.05 were considered statistically significant.
Results
High FHOD1 and FMNL1 mRNA expression associate 
with poor overall survival in intestinal gastric cancer
To assess the prognostic significance of FHOD1 and FMNL1 
expression in intestinal gastric cancer, we used the KM-plot-
ter database for Kaplan–Meier survival analyses [17]. The 
overall survival (OS) of patients was significantly reduced 
with both high FHOD1 (HR 2.07, 95% CI 1.51–2.83, 
p = 4.2e–06) and high FMNL1 (HR 2.18, 95% CI 1.58–3, 
p = 9.4e–07) mRNA expression. The plots are presented in 
Fig. 1a, b, respectively. We also tested, whether correlation 
between FHOD1 and FMNL1 expression and survival was 
dependent on other relevant clinical parameters, but found 
that the variables did not affect the correlation significantly.
Characterization of FHOD1 and FMNL1 expression 
in cultured gastric cancer cells
To characterize FHOD1 and FMNL1 expression in gastric 
cancer cell lines and validate antibodies for tissue stainings, 
we studied FHOD1 and FMNL1 protein expression in three 
publicly available cell lines; MKN28, AGS and MKN45. 
All studied cell lines displayed intermediate to high expres-
sion of FHOD1, and low expression of FMNL1 (Fig. 2a, 
b, respectively). We did not detect any distinct differences 
in the expression levels between the different cell lines. To 
study the localization and expression pattern of these form-
ins in gastric cancer cells, we performed double immuno-
fluorescence staining of F-actin and FHOD1 or FMNL1 in 
MKN28, AGS and MKN45 cells (Fig. 2c, d, respectively). 
FHOD1 was expressed mostly in a dot-like pattern in the 
cytoplasm and along the actin filaments of all cell lines. 
FMNL1 distribution was cytoplasmic for all studied cell 
lines. Negative staining controls showed no unspecific stain-
ing (Supplementary Fig. S1).
Expression of FHOD1 and FMNL1 
in the non‑neoplastic gastric mucosal lining 
and clinical samples of intestinal gastric cancer
To determine the baseline staining intensities of FHOD1 
and FMNL1, we studied non-neoplastic controls of gastric 
mucosa included in the TMAs. FHOD1 and FMNL1 stain-
ing intensity were low or negative in non-neoplastic gastric 
epithelium (Fig. 3a). The endothelium and plasma cells dis-
played positive staining for FHOD1, whereas lymphocytes, 
stromal cells and muscle cells stained positive for FMNL1. 
Based on these observations, we subsequently regarded the 
endothelial staining and plasma cells as internal positive 
controls for FHOD1 stainings in the tumor samples, and 
lymphocytes and muscle cells were, respectively, regarded 
as internal positive controls for FMNL1. In cancer cells, 
FHOD1 and FMNL1 showed different intensities of cyto-
plasmic expression. The stainings were scored as 0 (nega-
tive), 1 (weak), 2 (intermediate) or 3 (strong) (Fig. 3b). The 
expression of FHOD1 could be assessed in 177 (93%) cases, 
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Fig. 1  Prognostic significance of FHOD1 and FMNL1 mRNA expression in intestinal gastric cancer samples. a Kaplan–Meier plot (OS) of 
FHOD1 mRNA expression. b Kaplan–Meier plot (OS) of FMNL1 mRNA expression
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while FMNL1 could be assessed in 184 (96%) cases in the 
same TMAs.
Correlation of FHOD1 and FMNL1 expression 
with clinical variables among intestinal gastric 
cancer subtypes
To assess the clinical significance of FHOD1 and FMNL1 
expression in intestinal-type gastric cancer, we studied 
the correlation between clinical variables such as tumor 
size, stage and tumor location as well as molecular tumor 
subtypes (TP53, MMR and EBV status) and FHOD1 and 
FMNL1 expression. The FHOD1 stainings were catego-
rized in two groups: (1) negative/weak and (2) intermedi-
ate/strong, while FMNL1 stainings were categorized in 
three groups: (1) negative/weak, (2) intermediate and (3) 
strong. The results are presented in Table 2, significant 
p values are indicated in bold. Intermediate FMNL1 
expression in the peripheral tumor part associated signifi-
cantly with higher tumor size (T3: 43% and T4: 36.7%, 
p = 0.023) and samples with high FMNL1 expression 
were exclusively either T3 or T4 tumors (50%/50%). 
There was also a similar trend with FHOD1 expression 
in the central tumor part, but this association was not sta-
tistically significant (T3: 39.3% and T4: 35%, p = 0.069). 
In addition, elevated FMNL1 expression correlated sig-
nificantly with tumor stage (p = 0.004) regardless of the 
sample location (central or peripheral). Tumors with 
intermediate FMNL1 expression were primarily either 
stage II or stage III (43.6% and 35.6%, respectively) and 
tumors with high FMNL1 expression were mostly stage 
II or stage IV tumors (54.5% and 27.3%, respectively). 
Tumors with negative FHOD1 expression in their cen-























































Fig. 2  FHOD1 and FMNL1 expression and cellular localization in 
gastric cancer cell lines. a, b FHOD1 and FMNL1 expression levels 
in AGS, MKN28, and MKN45. GAPDH was used as a control for 
protein loading. c, d FHOD1 and FMNL1 cellular localization and 
expression pattern in GC cells. Actin filaments are stained with Alexa 
Fluor 488-conjugated phalloidin. Scale bars: 20 µm
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(77.1%, p = 0.007), while FMNL1 expression was not sig-
nificantly associated to any of the molecular subtypes. We 
also studied the prognostic significance of FHOD1 and 
FMNL1, but neither of these formins showed significant 
association with disease outcome (OS or RFS) in this 
patient cohort.
Association of FHOD1 and FMNL1 expression 
with intratumoral lymphocyte infiltration
In our previous study, we stained immune cell markers 
CD3, CD8 and FOXP3 from the same ngTMA utilized in 






























































































Fig. 3  Immunohistochemical staining of FHOD1 and FMNL1 and 
association of high FHOD1 expression and intratumoral lymphocyte 
infiltration in intestinal gastric cancer. a Examples of FMNL1 and 
FHOD1 stainings in non-neoplastic gastric mucosa. b. Examples of 
FHOD1 and FMNL1 staining intensities and scoring. c, d: Analysis 
of correlation between FHOD1 expression and number of infiltrated 
lymphocytes (mean value) in central (c) and peripheral (d) tumor 
parts. The boxes refer to quartile distribution (25–75%) range, with 
the median value shown as a vertical line. Statistical significance is 
indicated with stars: *p < 0.05; **p < 0.01; ***p < 0.005
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CD3- and CD8-positive lymphocytes was significantly 
associated with better outcome [24]. To find out whether 
there was any association of FHOD1 or FMNL1 expres-
sion with intratumoral lymphocyte infiltration in these 
TMA samples, we tested the correlation between FHOD1 
and FMNL1 expression and the number of CD3-, CD8- 
and FOXP3-positive lymphocytes in individual samples. 
The analyses showed that tumors with intermediate or high 
tumor cell FHOD1 staining intensity harbored significantly 
higher numbers of CD8-positive cells (p = 0.039 in central 
and p = 0.003 in peripheral part) than tumors with negative 
or weak FHOD1 expression (Fig. 3c, d, respectively, and 
Table 3). A similar trend was seen with CD3 + T lympho-
cytes in central tumor samples, but this observation was not 
statistically significant (p = 0.090). Samples with very high 
average CD8 + and CD3 + numbers (outliers) were exclu-
sively among tumors with intermediate or high FHOD1 
expression. Tumor cell FMNL1 expression did not correlate 
with lymphocyte infiltration.
Discussion
The crucial contribution of formins to cell migration and 
invasion is well established in many cancers, but their 
expression and function in gastric cancer (GC) remains 
mostly uncovered. Here, we characterized the expression 
patterns of FHOD1 and FMNL1 formins in clinical samples 
of non-neoplastic gastric tissue and intestinal GC and in GC 
cell lines, and investigated their potential clinical signifi-
cance. We focused here on intestinal-type tumors only, as 
their biologic origin is distinct from the diffuse type gastric 
cancer. Our study cohort includes also tumors from the gas-
tro-esophageal junction and distal esophagus, which share 
the molecular and morphological characteristics of intesti-
nal-type gastric cancer, especially the TP53 mutant (CIN) 
and the EBV-/TP53WT/MMR-proficient (other) subtypes [4, 
20].The expression was correlated with important clinical 
variables and different molecular subtypes of intestinal GC. 
In addition, we analyzed the correlation of FHOD1 and 
FMNL1 expression with intratumoral T lymphocyte infil-
tration in the same samples. To our knowledge, this study 
is the first to utilize clinical tissue samples in examining the 
role of FMNL1 and FHOD1 in intestinal-type GC.
Recently, elevated expression of FMNL1 and FMNL3 
mRNAs were associated with poor prognosis and immune 
infiltration in GC in a study by Nie et al. [25]. The analyses 
were conducted using several publicly available online data-
bases containing mRNA expression data. We found similar 
association of high FHOD1 and FMNL1 mRNA expression 
with poor outcome using an online database km-plotter [17]. 
However, when assessing the cancer cell-specific FHOD1 
and FMNL1 protein expression in intestinal GC tissue sam-
ples, we did not find direct prognostic significance (OS or 
PFS) for high FHOD1 or FMNL1 expression. As FHOD1 
and FMNL1 are prominently expressed in lymphocytes and 
macrophages in certain tissues [16, 26], we hypothesize 
that this difference may arise from technical issues. RNA 
analyses are typically performed from tissue bulk containing 
not only cancer cells but also mesenchymal cells, includ-
ing FHOD1 and FMNL1 expressing immune cells. This can 
lead to an overestimation of the cancer cell-specific mRNA 
expression, while in our approach, we only analyzed cancer 
cell-specific FHOD1 and FMNL1 staining and disregarded 
the strongly stained immune cells from our scoring results. 
Nie et al. also state in their report that high formin mRNA 
expression negatively correlated with tumor purity, indicat-
ing that in tumors with high FMNL1 expression, less cancer 
cells were present [25].
We further characterized FHOD1 and FMNL1 protein 
expression levels and patterns in gastric cancer cells. We 
chose cell lines representing well differentiated (MKN28) 
and poorly differentiated (AGS, MKN45) GC. The cell stain-
ings showed typical dot-like expression patterns and cyto-
plasmic location along the actin filaments, which have been 
previously reported in other cancer cell types [7, 8, 20]. This 
Table 3  Association of FHOD1 
tumor cell expression with 
tumor lymphocyte infiltration
Statistically significant p values are indicated in bold
Central tumor sample Peripheral tumor sample
N Mean Min Max p value N Mean Min Max p value
CD8 + average
 FHOD1 neg/weak 40 53.5 2.7 168.5 0.039 19 42.5 2.1 103.5 0.003
 FHOD1 interm/high 143 71.7 0.8 345.6 132 71.7 0.9 402.0
CD3 + average
 FHOD1 neg/weak 40 85.9 15.2 257.3 0.090 19 70.8 4.0 171.4 0.216
 FHOD1 interm/high 143 104.9 2.5 429.9 132 96.4 4.0 508.0
FOXP3 average
 FHOD1 neg/weak 40 25.1 2.0 83.0 0.614 19 22.5 0.2 104.8 0.708
 FHOD1 interm/high 143 27.2 0.3 116.7 133 24.9 0.3 123.0
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cytoplasmic pattern was recapitulated in the gastric cancer 
tissue samples, further confirming the integrity of the immu-
nohistochemical stainings. Non-neoplastic tissue samples 
displayed negative or weak expression of both FHOD1 and 
FMNL1. FHOD1 was strongly expressed in endothelium and 
plasma cells, whereas strong FMNL1 was seen in lympho-
cytes, stromal spindle cells and muscle cells. Using these as 
internal positive controls for the tumor sample stainings, we 
were able to enhance the quality of our analysis and confirm 
the tumor cell-specific scoring.
Importantly, even though no direct prognostic signifi-
cance was seen, both FHOD1 and FMNL1 expression asso-
ciated with other clinical parameters. Elevated expression 
of FMNL1 was associated with larger tumor size and with 
more advanced disease stage. Also, FHOD1 expression was 
elevated in larger tumors, but statistical significance was not 
achieved. These results indicate that FMNL1 may have a role 
in GC tumor progression. A similar association has been 
seen in other cancers [8, 27].
We have previously described an easily adaptable method 
for identifying distinct molecular subtypes among intestinal 
gastric cancer, based on immunohistochemical and in situ 
hybridization markers [21]. In this study we analyzed the 
association of FHOD1 and FMNL1 expression with the 
molecular subtypes and found that TP53-mutated sub-
type was associated with negative or weak FHOD1 stain-
ing. This indicates a possible down-regulation of FHOD1 
in TP53-mutated tumors. One of the pathways altered in 
TP53-mutated GC is the phosphatidylinositol-3-kinase 
(PI3K–AKT) [4], which is essential in the control of FHOD1 
expression [10]. While the mechanism governing the con-
nection between TP53 and FHOD1 remains unclear, there 
are mutual links indicating the need for further investigation.
Our previous study with the same GC cohort showed that 
increased numbers of intratumoral CD3 + and CD8 + T lym-
phocytes were associated with a favorable outcome [24]. 
Here, we wanted to investigate whether intratumoral T lym-
phocyte infiltration and formin expression in the same tissue 
samples are interconnected. Indeed, we found a correlation 
between tumor cell FHOD1 expression and high numbers 
of CD8 + lymphocytes. TP53-mutated GC tumors generally 
display lower intratumoral lymphocyte infiltration and wild-
type TP53 tumors, in turn, harbor high numbers of infiltrat-
ing lymphocytes [24]. We found down-regulation of FHOD1 
in TP53 aberrant tumors and upregulation of FHOD1 in 
tumors with high lymphocyte infiltration. In contrast to a 
previous finding [25], such association was not seen with 
tumor cell FMNL1 expression and number of infiltrated 
lymphocytes.
Although prognostic significance for the studied formins 
could not be recapitulated in immunohistochemical analy-
ses, the study describes novel data on formin expression, 
cellular localization and possible correlation with immune 
cell recruitment in intestinal GC. Furthermore, our results 
demonstrate a correlation between FMNL1 expression and 
tumor size as well as tumor stage, suggesting that FMNL1 
may play a role in tumor progression in intestinal GC.
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